The Frax Pro System Launches

What To Know

  • These innovations, along with magnetic roller sensing technology and integrated clinical intelligence for quick learning and data retrieval, are just some of the ways that the Frax Pro system advances the space of non-ablative fractional laser therapies, making it the “smart way to Frax”.
  • High return on investment (ROI) treatments of the Frax Pro system make it a wise approach to managing practice costs when compared to a leading competitive device.

The Frax Pro System, FDA-cleared, non-ablative fractional device is the first platform featuring dual-depth skin resurfacing with both Frax 1550™ and the novel Frax 1940™ applicators.

Candela today announced the availability of the Frax Pro™ system.

The two modalities target different skin layers, stimulating growth of new collagen, revealing smoother, more brilliant skin. The Frax 1940 handpiece delivers a 1940 nm wavelength laser beam for a shallow, epidermal approach, with focal reach extending to approximately 200 μm in depth. The 1550 nm wavelength of the Frax 1550 handpiece penetrates deeper, with histological analysis showing up to 800 μm penetration. Clinical studies demonstrate high rates of textural improvement and patient satisfaction with the Frax 1550 and Frax 1940 handpieces.

“With use of both applicators achieving dual depth resurfacing, we saw a complementary effect,” says Jill Waibel, MD of Miami Dermatology and Laser Institute. “Additionally, patients treated in our clinic were extremely pleased with new Frax 1940 treatment results. The outcomes clearly demonstrated intended results of skin resurfacing with improvement in both textural irregularities and skin tone.”

The Frax Pro system revolutionizes the aesthetic space by removing limitations of earlier fractional 1550 nm, 1565 nm and/or 1927 nm laser systems. High return on investment (ROI) treatments of the Frax Pro system make it a wise approach to managing practice costs when compared to a leading competitive device. The Frax Pro system’s exclusive 100% applicator-confined diode laser technology and a reductive design, allows a lightweight, flexible umbilical for a comfortable, ergonomic reach and improved treatment visibility relative to thulium-based systems.

Multiple laser scan widths enable more customized treatments. These innovations, along with magnetic roller sensing technology and integrated clinical intelligence for quick learning and data retrieval, are just some of the ways that the Frax Pro system advances the space of non-ablative fractional laser therapies, making it the “smart way to Frax”.

Both the Frax 1550 and Frax 1940 technologies are also available on, and interchangeable with, the NordlysTM platform. This addition makes the Nordlys system the first in its class to provide dual fractional 1550 nm and 1940 nm wavelengths, as well as IPL and Nd:YAG capabilities.

“The Frax Pro and Nordlys systems, both with Frax 1550 and Frax 1940 applicators, extend our legacy of innovation in non-ablative treatments,” says Geoffrey Crouse, Chief Executive Officer of Candela. “Candela has a long history of technological innovation and bringing to market best-in-class medical aesthetic energy-based devices, and we are proud to share this new offering.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Reeva FT is offered in a variety of sizes: 2x2 cm, 2x3 cm, 4x4 cm, 4x6 cm, 4x8 cm, and 10x15 cm. Reeva FT is confirmed by the FDA Tissue Reference Group to meet the criteria for regulation solely under Section 361 of the PHS Act as defined in 21 CFR Part 1271.
The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).
“Tom and I have more than 50 years of experience,” Harp adds. “The decision to found Polymer Medical was done after careful consideration of the landscape and market opportunity; we will raise the level of competition and quality for customers.” Polymer Medical is located in a newly refurbished plant is at 168 Thorn Ave., Orchard Park, N.Y.
The RWE Program will expand Summus Laser's Class IV Laser Therapy research to generate validated and statistically significant datasets that will be used to enhance patient care, outcomes, and to further product innovations.
Details of the session: Polaroid Therapeutics & Avery Dennison Medical: How the power of partnership brings a novel approach to antimicrobial wound dressings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy